PPCB

Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office

Retrieved on: 
Tuesday, April 16, 2024
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, IP, Trypsinogen, European Patent Convention, Chymotrypsinogen, EFPIA, United States of Europe, Statista, PRP, Patent, Patient, OTC Markets Group, PPCB, Pharmaceutical industry

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s “composition of proenzymes for cancer treatment,” patent was received from the European Patent Office.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s “composition of proenzymes for cancer treatment,” patent was received from the European Patent Office.
  • The patent covers lower dosage ratios of the two proenzymes (trypsinogen and chymotrypsinogen) contained in the PRP formulation.
  • This is the fourth European patent granted and after validation in selected countries across Europe, will result in the Company’s IP portfolio growing to 94 patents filed in major global jurisdictions.
  • This is a significant percentage when you consider that in 2022, the worldwide pharmaceutical market was valued at approximately $1.48 trillion by Statista.com.

Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing

Retrieved on: 
Monday, April 8, 2024
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, OTC Markets Group, Communication, AP, PPCB, Corporate title, Patient, Cancer, APS, Atmosphere, Drug development, Safety, Due diligence, Pharmaceutical industry

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s CEO, Mr. James Nathanielsz, shares his views on revolutionizing cancer treatment with an inside look at drug development and strategic financing.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s CEO, Mr. James Nathanielsz, shares his views on revolutionizing cancer treatment with an inside look at drug development and strategic financing.
  • Mr. Nathanielsz appeared on a show with Mr. Joel Block, a weekly podcast on killer business strategies and how the best leaders make them work.
  • In this week’s episode, Mr. Nathanielsz discusses the competitive advantage of the Company and its enzyme treatment for metastatic cancer.
  • Some key points to the competitive advantage highlighted by Mr. Nathanielsz include:
    Global Financing Strategy: Mr. Nathanielsz emphasizes the company's global view on accessing funds and its current pursuit of series A financing, showcasing a strategic approach to securing financial support.

Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study

Retrieved on: 
Thursday, February 22, 2024
Biotechnology, FDA, Health, General Health, Pharmaceutical, Oncology, Research, Surgery, Genetics, Science, Clinical Trials, Breast, Stomach, EST, Prostate, PPCB, OTC Markets Group, Life expectancy, Patient, Melanoma, Pharmaceutical industry

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancers, today announced that members of the management will host a corporate update call on March 28, 2024, at 2:00 p.m., EST, to dive into the recent corporate updates and exciting positive results produced from a compassionate use study leveraging Propanc’s proenzyme therapy.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancers, today announced that members of the management will host a corporate update call on March 28, 2024, at 2:00 p.m., EST, to dive into the recent corporate updates and exciting positive results produced from a compassionate use study leveraging Propanc’s proenzyme therapy.
  • The compassionate use study results highlight clinical effects studied in 46 patients with advanced metastatic cancers of different origin (prostate, breast, ovarian, pancreatic, colorectal, stomach, non-small cell lung, bowel, and melanoma) after treatment with a rectal formulation of pancreatic proenzymes.
  • Nineteen of 46 patients (41.3%) with advanced malignant diseases, most of them suffering from metastases, had a survival time significantly longer than the expected life span (mean survival of 9.0 months vs life expectancy of 5.6 months), with no severe or serious adverse events related to administration.

Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office

Retrieved on: 
Tuesday, January 16, 2024
Research, Other Health, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, PPCB, OTC Markets Group, Patient, EFPIA, IP, PRP, Propane, Invention, CSCS, Cancer, Quality of life, Recurrence, Patent, United States of Europe, News, Statista, Pharmaceutical industry

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s foundation patent was received from the Canadian Intellectual Property Office.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s foundation patent was received from the Canadian Intellectual Property Office.
  • The foundation patent covers composition claims for the Company’s lead product candidate, PRP.
  • The Canadian foundation patent is the final application to receive a certificate of grant in the Company’s foundation patent family (there are two divisional patents remaining citing additional inventions in the US and Mexico further dividing an original patent,).
  • This means that grant status has been secured in every jurisdiction in which the Company has filed a foundation patent application.

Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities

Retrieved on: 
Monday, December 18, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, PPCB, PRP, Malignancy, Chymotrypsinogen, Neoplasm, Cancer, Patient, Prognosis, Cell, Metastasis, OTC Markets Group, Pharmaceutical industry

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a boutique advisory firm has been engaged to identify strategic investment opportunities primarily to fund the advancement of the Company’s lead product candidate, PRP, to the completion of the Company’s planned Phase I, First-In-Human study in advanced cancer patients suffering from solid tumors.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a boutique advisory firm has been engaged to identify strategic investment opportunities primarily to fund the advancement of the Company’s lead product candidate, PRP, to the completion of the Company’s planned Phase I, First-In-Human study in advanced cancer patients suffering from solid tumors.
  • As part of the process, the opportunity to consider up-listing to a national US stock exchange will also be considered.
  • The emerging boutique advisory firm currently has a $3B+ transaction history and access to a global network of investors the Company intends to fully utilize.
  • PRP, a combination of two proenzymes trypsinogen and chymotrypsinogen, is a novel, targeted therapy for the treatment and prevention of metastatic cancer.

Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP

Retrieved on: 
Wednesday, December 13, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, PPCB, Lung, PRP, Pancreatic cancer, Prostate, Breast, Brain, Skin, OTC Markets Group, US Foods, Liver, Trypsinogen, Patient, Kidney, Neoplasm, Interview, MB, MD, Cancer, Georgetown University Medical Center, Survival, Growth, Chymotrypsinogen, Pharmaceutical industry

Research by this team of scientists, led by Professor Elisa Giovanetti, focuses on chemotherapy resistance in pancreatic cancer.

Key Points: 
  • Research by this team of scientists, led by Professor Elisa Giovanetti, focuses on chemotherapy resistance in pancreatic cancer.
  • “Chemotherapy is still considered an irreplaceable front-line therapeutic strategy to treat cancer.
  • But multidrug resistance represents a common hurdle that profoundly compromises clinical outcomes, especially in pancreatic cancer.
  • Tumor resistance to frontline chemotherapy means a poor prognosis for survival, especially in pancreatic cancer.

Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells

Retrieved on: 
Tuesday, November 7, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, MB, Neoplasm, Metastasis, OTC Markets Group, Cancer, MD, US Foods, Liver, Doctor of Philosophy, Phenotype, Kidney, Trypsinogen, Malignancy, Extracellular matrix, Tissue, Lung, Growth, Chymotrypsinogen, Survival rate, Skin, Pancreatic cancer, University, Gene, Master of Science, Brain, Tumor microenvironment, Bachelor of Medicine, Bachelor of Surgery, PDAC, Apoptosis, Patient, Breast, Gene expression, PRP, Prostate, PPCB, Medical imaging, Pharmaceutical industry

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy (ability to spread into surrounding tissues).

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy (ability to spread into surrounding tissues).
  • Various methods, including apoptosis (programmed cell death) and viability analysis, live/dead assays, and RT-qPCR (real time quantification of gene expression) analyses confirmed PRP enhances the sensitivity of pancreatic tumor cells to standard chemotherapy treatment and decreases expression of genes related to chemoresistance.
  • A synergistic ratio of 1:6 inhibits growth of most tumor cells.
  • Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (FDA) for treatment of pancreatic cancer.

Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia

Retrieved on: 
Tuesday, August 15, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, OTC Markets Group, PPCB, Pancreatic cancer, US Foods, Australian government debt, Education, Skin, Clinical trial, Trial of the century, Cancer, Pharmacokinetics, Breast, Innovation, Brain, Prostate, Government, Movement, Lung, PRP, Patient, Chymotrypsinogen, BAS, Trypsinogen, Kidney, FIH, Growth, Liver, MEI, Clinical, Food, Pharmaceutical industry

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company will target the Peter Mac Cancer Center in Melbourne, Australia, as the site for the First-In-Human (FIH) study for PRP in patients with advanced solid tumors.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company will target the Peter Mac Cancer Center in Melbourne, Australia, as the site for the First-In-Human (FIH) study for PRP in patients with advanced solid tumors.
  • This includes the finished drug product manufacture and validation of the bioanalytical method to analyze the pharmacokinetics (movement of drug within the body) of PRP during the study.
  • The Peter Mac Cancer Center is a world leading cancer research, education and treatment center and Australia’s only public health service dedicated to caring for people affected by cancer.
  • Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (FDA) for treatment of pancreatic cancer.

Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030

Retrieved on: 
Tuesday, July 25, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Vaccine, Molecular biology, OTC Markets Group, PPCB, Pancreatic cancer, ODE, Orphan Drug Act of 1983, US Foods, Prevalence, MB, Skin, Lymphatic system, Survival, Breast, Brain, Tobacco, Prostate, Life expectancy, Lung, Incidence, ODA, US, Bachelor of Medicine, Bachelor of Surgery, PRP, MD, Patient, Chymotrypsinogen, Trypsinogen, Kidney, Liver, Growth, R, Food, Disease, Pharmaceutical industry

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s clinical candidate PRP targeting the pancreatic cancer market is forecast to reach $6.93 Billion by 2030, according to a report published by The Brainy Insights, a market research company.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s clinical candidate PRP targeting the pancreatic cancer market is forecast to reach $6.93 Billion by 2030, according to a report published by The Brainy Insights, a market research company.
  • According to the report, the global pancreatic cancer market is expected to grow at a compound annual growth rate (CAGR) of 8.13% during the forecast period between 2022 to 2030.
  • As a result of laboratory and clinical studies undertaken in pancreatic cancer, Propanc applied for and received Orphan Drug Designation from the US FDA for the use of PRP to treat pancreatic cancer.
  • Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (FDA) for treatment of pancreatic cancer.

Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads

Retrieved on: 
Thursday, July 13, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, Survival rate, OTC Markets Group, PPCB, Pancreatic cancer, US Foods, MB, Life, Skin, Proprietary company, Neoplasm, Alternative medicine, Survival, EMT, ANOVA, Cancer, Breast, University, Toxicity, Brain, ResearchGate, Prostate, Teaching hospital, Lung, Death, National Cancer Institute, Bachelor of Medicine, Bachelor of Surgery, PRP, MD, Patient, BAS, Chymotrypsinogen, Scientific Reports, Trypsinogen, Kidney, Liver, Growth, MEI, Ovarian cancer, US FDA, Disease, Pharmaceutical industry, Nature

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a peer reviewed scientific article published by the Company and its research partners reached 3,000 reads on July 6, 2023, according to ResearchGate.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a peer reviewed scientific article published by the Company and its research partners reached 3,000 reads on July 6, 2023, according to ResearchGate.
  • The EMT is a mechanism by which cancerous cells become motile and invasive, as well as immortal, thus seeding new tumors.
  • We have published scientific and clinical data in peer reviewed journals providing evidence that PRP can become an effective tool in the fight against cancer.
  • Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (US FDA) for treatment of pancreatic cancer.